Gastrointestinal

Lanzofutal
  • Active Substance (s) : Lansoprazole 15 mg and 30 mg
  • Dosage Form : Hard Gelatin Capsules Containing Delayed Release Pellets
  • Pack : 10 capsules/bottle
  • Indication :
    • Treatment of duodenal and gastric ulcer
    • Treatment of reflux oesophagitis
    • Prophylaxis of reflux oesophagitis
    • Eradication of Helicobacter pylori (H
    • pylori) concurrently given with appropriate antibiotic therapy for treatment of H
    • pylori-associated ulcers
    • Treatment of NSAID-associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment
    • Prophylaxis of NSAID-associated gastric ulcers and duodenal ulcers in patients at risk requiring continued therapy
    • Symptomatic gastroesophageal reflux disease
    • Zollinger-Ellison syndrome
  • Product Description : Lanzofutal inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach
  • Recommended Daily Dosage :
    • The recommended dose is 30 mg once daily for 2 weeks